Contact us

Our Purpose

The primary focus of our work at SEDA is to add value to our Clients.

We achieve this through the pragmatic application of scientific excellence in Pharmaceutical Technology and Clinical Pharmacology. Our ambition is to provide our Clients with the experience and level of expertise that may be found in the development functions of major pharmaceutical companies but with the speed and flexibility required in the fast moving biotech sector.

Our knowledge and experience allow us to quickly identify the essential experiments for the phase of development and deliver a suitable data package to meet the regulatory expectations whilst ensuring that the clinical programme has the best chance of success. Equally important is our ability to identify work that can be delayed until after the next value inflection point to ensure that the spend profile is managed appropriately.

We understand that speed is of the essence, particularly in early stages of development, and we ensure that our systems and process have the agility to stay off the critical path.

We know that if we can contribute to the value proposition of our Clients, we will play our part in bringing new, innovative therapies to patients.

Ask our team a question

Expertise:

  • Oral Drug Delivery
  • Complex Parenterals
  • Paediatric Product Development
  • Regulatory CMC

Paul W Stott

BPharm (Hons) PhD

Director & CEO

Paul W Stott

BPharm (Hons) PhD

Director & CEO

View Bio Ask me a question

Paul is an established pharma executive with extensive global experience. Prior to joining Seda he was Vice President, Global Product Development at AstraZeneca, leading a group of over 350 scientists and engineers in the development of all products, manufacturing processes and analytical methods for the AstraZeneca small molecule portfolio.

AstraZeneca Global Product Development has centres in the UK, Sweden, US and China and a network of partnerships with colleagues all over the world and under Paul’s stewardship registered 10 global products.

At AstraZeneca Paul was accountable for the Drug Product CMC component of all Due Diligence assessments and was CMC lead on several multibillion dollar acquisitions. In addition, Paul is a visiting Professor of Pharmaceutics at the University of Manchester, UK and founder of the North West Centre for Drug Delivery (NoWCADD) at the University.

He is a proven senior manager and strategic leader in Pharmaceutical Development with experience across geographical boundaries. Passionate about the development of individual and group capabilities and the application of innovation and scientific rigour to bring new medicinal products to market.

He is recognised within the Industry and with Regulatory Agencies as a driving force in the establishment and realisation of best practice in CMC Quality by Design.

Ask me a question

    Expect a reply typically within 48 hours.

    Expertise:

    • DMPK and Dose Selection
    • Pharmacokinetic Modelling
    • Complex Parenterals
    • Regulatory CMC
    • Clinical Pharmacology

    Paul A Dickinson

    BPharm (Hons) PhD

    Director & Co-Founder

    Paul A Dickinson

    BPharm (Hons) PhD

    Director & Co-Founder

    View Bio Ask me a question

    Paul has held several senior science leadership roles in Academia and Large Pharma.  These roles focused on applying the best science in projects to ensure optimal product performance in the patient, thus bridging pharmaceutical and clinical disciplines.

     

    Immediately prior to founding Seda Pharmaceutical Development Services Paul was Senior Clinical Pharmacology Scientist at AstraZeneca and led the clinical pharmacology program to NDA/MAA for AZD9291/osimertinib, which had been awarded ‘breakthrough therapy’ status by the FDA.  Formerly Paul was a Principal Scientist within Pharmaceutical Development (AZ) leading both the global biopharmaceutics network and the Medicines Evaluation science community (USA, SE, UK).

     

    Paul has been at the forefront of recent advances in the understanding of in vitro performance criteria that assure product performance in the patient including clinically relevant dissolution specifications (CRDS).  Paul has co-authored papers with FDA staff focussed on efforts to combine biopharmaceutics with ICH Q8 (BioRAM) and is past Chair of the AAPS ‘QbD and product performance’ focus group.

     

    Ask me a question

      Expect a reply typically within 48 hours.

      Expertise:

      • Oral Drug Delivery
      • Complex Parenterals
      • Paediatric Product Development
      • Regulatory CMC
      • Analytical Sciences

      Marcel de Matas

      BSc (Hons) PhD FRSC CChem

      Director & Co-Founder

      Marcel de Matas

      BSc (Hons) PhD FRSC CChem

      Director & Co-Founder

      View Bio Ask me a question

      Marcel has a track record in a range of management and senior scientific positions in industry and academia. Most recently he was a Principal Scientist in Product Design and Innovation at AstraZeneca, where he was responsible for introducing the latest science, new technologies (advanced drug delivery and manufacturing) and product design thinking into the Product Development group.

      Marcel has led technical activities, provided project leadership and has managed product development teams responsible for the delivery of drug projects from initial concept design through late stage development, regulatory submission and launch (including advanced drug delivery systems). He has led teams at the drug discovery-development interface, assessing the level of chemistry manufacturing and controls (CMC) technical risk and defining product design strategies in early development. Project experience has covered projects across a range of disease and therapy areas with substantial experience in the oncology field.

      Ask me a question

        Expect a reply typically within 48 hours.